Breast Cancer Active Surveillance, Alternative Option, Aspirin Included
Status:
Not yet recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
Experimental, clinical, and epidemiological studies have all demonstrated the strong
association between chronic inflammation and cancer, and many studies have correlated the
prolonged presence of the inflammatory milieu with an increased risk for developing
cancer.(1) Although the potential mechanism for aspirin preventing breast cancer is not
known, possible pathways may involve platelets, inflammation, cyclooxygenase (COX) 2,
hormones, or PI3 kinase. (2).
In actual clinical practice there exist clear guidelines for the use of aspirin in colorectal
cancer but no such guidelines exist for the use of aspirin in breast cancer patients.
In the Unit´s proper experience, in patients under active surveillance and metastatic ones
some present very good responses both in the neoadjuvant and in the metastatic setting but
investigators intend to provide evidence and not just the experience. This study patients are
proposed to combine their standard treatment with aspirin.